MAPK3 and acute lymphoblastic leukemia: Furthermore, co-treatment of AZD6244 with X-370 significantly enhanced activity against X-370-insensitive primary B-ALL cells (Figure 6B), and combination treatment was accompanied with decreased phosphorylation of Erk1/2 (Figure 6C).